LEIDEN, NETHERLANDS--(Marketwire - August 26, 2011) - Today Batavia Bioservices BV and Xendo
BV announce that they have initiated a
strategic business collaboration. As a consequence, all Bioprocess
Xendo Manufacturing BV have been transferred to Batavia Bioservices BV.
provides Batavia Bioservices BV access to unique simulated moving bed (SMB)
purification technology as well as infrastructure, knowledge and experience
microbial process and product development. At the same time, the companies
establish joint marketing efforts whereby Xendo BV will provide
regulatory and clinical support services and Batavia Bioservices will
process development and analytical services.
Menzo Havenga (CEO, Batavia Bioservices BV) explains: Xendo BV and Batavia
Bioservices BV together have more critical mass and therefore are able to
execute larger, more complex customer programs. It is fully expected that
collaboration will result in more customers being offered a complete
services package. André van de Sande, CEO Xendo BV, adds: I trust that
combining our forces both companies are better positioned to service our
customers. This helps Xendo BV, both in the Netherlands and international,
Information on Xendo BV
Xendo is a leading, independent consultancy and project management
in the life sciences, pharmaceutical and healthcare fields. Our ambition is
enhance the quality and safety of medicine and help shorten the time to
for drugs and medical devices that improve the quality of life.
Xendo was established in 1990 (originally under the name of Univalid) and
fully privately owned.
Xendo has offices in Leiden (headquarter) and in Berlin. The company
close to a hundred employees and has its own in-house QA and Knowledge
management center and is ISO 9001 certified.
More information on Xendo can be found on www.xendo.com
Information on Batavia Bioservices BV:
Batavia Bioservices is a biopharmaceutical process development services
dedicated to add value to customers by providing high quality
for proof-of -concept and pre-clinical product development studies. The
focuses on the early stages of product development with services ranging
cloning and mammalian cell line generation, to upstream process
purification and product characterization. Headquartered in Leiden, The
Netherlands, Batavia Bioservices is privileged to have strong strategic
in both the Netherlands and the United States of America. Batavia
a limited liability company that is not publicly traded. More information
Batavia Bioservices can be found on www.bataviabioservices.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Batavia Bioservices B.V. via Thomson Reuters ONE